Tanneeru Srihari’s Post

In 2023, several research findings related to endometriosis have emerged. Some of the latest advancements include: 1. A study published in Science Translational Medicine found that endometriosis may be caused by a bacterial infection. This discovery could potentially lead to new treatments and a better understanding of the condition. 2. A global study revealed compelling evidence of a shared genetic basis for endometriosis and other types of pain seemingly unrelated to endometriosis. This finding could help researchers develop more targeted treatments for endometriosis. 3. A potential new treatment for endometriosis is being tested in a groundbreaking clinical trial involving 100 women in Edinburgh and London. The trial aims to assess whether the drug dichloroacetate helps relieve pain, which could be the first non-hormonal, non-surgical treatment for endometriosis. 4. Research has shown that pelvic floor therapy could be key to tackling endometriosis-induced pain. A 2021 study showed that incorporating pelvic floor therapy as part of a lifestyle could help women with deeply infiltrative endometriosis (DIE) – a type of endometriosis that can invade the pelvic cavity. These findings contribute to the ongoing research and development of new treatments and interventions for managing endometriosis, a condition that affects around 190 million women and girls globally. #EndometriosisAwareness #EndoWarrior #EndoStrong #EndoCommunity #EndoSupport #EndoSisters #EndoAdvocate #EndoLife #EndoAware #EndoFighter #EndoPain #EndoAwarenessMonth #EndoResearch #EndoHealth #EndoAwarenessCampaign

🔬 Join Fortrea for an upcoming webinar featuring pharma experts and patient organizations to discuss patient-centric approaches in #neurodegenerative disorder research. Expert speakers will explore advancements in precision medicine, including fluid and imaging biomarkers for patient identification, stratification, and treatment response monitoring. The session will highlight how integrating patient and caregiver input into clinical trials can enhance effectiveness and outcomes. Learn about the role of biomarkers and the necessity of extensive patient participation. ➡️ Register here + more info: https://buff.ly/4ehYO5v #AlzheimersDisease #ParkinsonsDisease #PrecisionMedicine #PatientCentricity #PatientRecruitment #TherapeuticAreas #ClinicalTrialEndpoints #NeurodegenerativeDisorders #ImagingBiomarkers #DigitalBiomarkers

#Diabetic #wounds, often resistant to conventional treatments, pose serious health risks to millions of people worldwide. #Immune cells known as #macrophages, which are supposed to help, end up causing #inflammation instead, making it harder for the wound to heal properly and quickly. Now, researchers from the Icahn School of Medicine at Mount Sinai and The Ohio State University have designed a #regenerative medicine therapy to speed up diabetic wound repair. Using #lipid #nanoparticles loaded with #RNA encoding a signaling protein known as a #cytokine, the therapy targeted dysfunctional macrophages while simultaneously reducing inflammation in diabetic wounds. "In preclinical models, we basically showed the therapy's ability to reprogram pro-inflammatory macrophages into reparative ones, leading to improved wound healing outcomes," said Yizhou Dong, one of the scientists involved in this study. https://lnkd.in/gqVgtuP6 (Work funded by The National Institutes of Health)

🚀 Exciting advancements in clinical trials! AnzuBridge's Media Capture and Review technology is transforming the way we approach the cure and treatment of various diseases. Revolutionizing clinical trials with advanced media capture to accelerate approvals, improve compliance, and enhance efficiency. Our technology makes it easier to capture and review videos of subjects performing various actions, which is critical for: 🧠 Neurodegenerative Diseases 💪 Muscular Disorders 🧬 Rare Genetic Conditions 👶 Pediatric Conditions ❤️ Cardiovascular Diseases 👁️ Vision and Hearing Disorders 🩺 Movement Disorders 🎗️ Oncology Trials With features like bookmarking and clipping, stakeholders and regulators can efficiently review and fast-track the approval of clinical trials, bringing treatments to patients faster. Discover how AnzuBridge can enhance your clinical trials today! 👉 Book a demo: https://lnkd.in/ebhkAnbV #NeurodegenerativeDiseases #MuscularDisorders #RareGeneticConditions #PediatricConditions #CardiovascularDiseases #VisionDisorders #HearingDisorders #MovementDisorders #OncologyTrials #ClinicalTrials #MedicalInnovation #HealthcareTech #RegulatoryApproval #PatientCare #MedicalResearch #Biotech #HealthTech #AnzuBridge #ClinicalResearch #LifeSciences

A groundbreaking achievement in biomedical research has emerged from the Indian Institute of Technology, Kanpur (IIT-K), delving into the realm of G protein-coupled receptors (GPCRs) and the chemokine receptor D6. ---------- For the latest in #healthcare, #medtech, #medicaldevices, #diagnostics and #medical world, follow MedTechAsia.in. ---------- #neurologicaldisorders #cancertreatment #healthcare #Medicine #health

[INNOVATION UPDATE] Donanemab to Treat Early Alzheimer’s disease Toxic accumulations of amyloid-beta (Aβ) protein in the brain, often called plaques, are thought to be key contributors to Alzheimer’s disease (AD) pathology. Donanemab (Kisunla) is a monoclonal antibody designed to bind to Aβ plaques and promote their clearance from the brain, thus slowing cognitive decline. Donanemab was approved by the U.S. Food and Drug Administration to treat patients with early symptomatic AD, including mild cognitive impairment as well as the mild dementia stage of AD, who have confirmed amyloid pathology. Want to learn more about this novel therapy? View the latest Emerging Health Care Innovation Brief: Emerging Healthcare Innovation Brief Volume 2 - Issue 15 (https://hubs.la/Q02KCv540) #alzheimersdisease #earlyalzheimers #dementia #neurology#patientcare #healthcare #innovation #horizonscanning #ecri

Exciting research on mice reveals a potential breakthrough in treating spinal cord injuries! When these injuries occur, certain nerve cells can swell up and stay that way, which may lead to cell death and hinder recovery. A study published in Science Translational Medicine found that a drug called bumetanide—typically used to treat swelling in humans—can reduce this harmful swelling and improve movement in injured mice. Using advanced techniques, researchers were able to observe over 30,000 nerve cells in the spinal cord. They discovered that while some cells return to normal size within two weeks, excitatory neurons (which boost activity in other cells) can remain swollen for much longer, sometimes up to 35 days. This prolonged swelling contributes to more cell death, affecting recovery. The good news? Mice treated with bumetanide showed better recovery in their ability to move after injury. While these findings are promising, more research is needed to determine if bumetanide could help humans with spinal cord injuries. This could lead to new treatment options and hope for many individuals facing these challenges. Read more: https://lnkd.in/gV6Hs3U6 Follow Us On Facebook: https://lnkd.in/gWdmrXJT Follow Us On Instagram: https://lnkd.in/gYf2idsV Follow Us On LinkedIn: https://lnkd.in/gwvUh4_7 #sif #scientificintelligenceforum #spinalcord #injury #spinalcordinjury #treatment

New paper: "Macro and micro structural preservation of grey matter integrity after 24 weeks of rTMS in Alzheimer’s disease patients: a pilot study"

Hypertrophic cardiomyopathy (HCM) is a cardiac disease in which several gene mutations affect its manifestation. HCM thickens heart walls and increases the risk of irregular heartbeats and sudden death. Affecting up to five in 1,000 people, it's the most common inherited cardiac disease and a leading cause of sudden death in young individuals. Despite the complexity of the disease, current approaches treat HCM as a single disease, resulting in less effective care. Enter SMASH-HCM, a €10 million EU project led by Tampere University, poised to revolutionize HCM management! SMASH-HCM develops a sophisticated digital twin – a digital replica of the heart and blood vessels, complemented by sympathetic nerve control and integrated with AI and clinical data. This advanced digital tool enhances risk assessment and enables tailored treatments for individual patients. Doctors gain improved diagnostics and can provide precise lifestyle advice. Moreover, the new tool supports healthcare, technology, and pharmaceutical industries by facilitating target discovery and cardiac safety testing. Ultimately, it promises superior treatments, outcomes, and global healthcare cost savings. 📸 Jonne Renvall / Tampere Uni #HCMawareness #DigitalHealth #PersonalizedMedicine #CardiologyInnovation #PatientCare #MedicalResearch #HealthTech #SMASHHCM

📃Scientific paper: Practical utility of the ACT-FAST triage algorithm from a primary stroke centre perspective Abstract: Background: Rapid reperfusion in ischaemic stroke with emergent large vessel occlusion (ELVO) reduces morbidity and mortality. Limited distribution of endovascular clot retrieval (ECR) capable comprehensive stroke centres (CSCs) necessitates development of pre-hospital models of care to provide equitable and economical access to reperfusion therapy. We examine the time metrics of the traditional secondary transfer strategy in comparison to the direct bypass strategy and the potential utility of the ACT-FAST prehospital triage algorithm on a large volume Melbourne primary stroke centre (PSC). Method: Retrospective analysis of consecutive patients presenting to a PSC from 1 January 2020 to 31 December 2020. Clinical records were interrogated for ACT-FAST positive patients. Time metrics were established using Google Maps traffic modelling and local/published door-to-needle, door-in-door out and door-to-groin data. Results: 88 patients during the study period were ACT-FAST positive. Of these, 49/88 (56%) cases had ELVO ischaemic strokes, 24/88 (27%) cases had intracranial haemorrhages and the remaining 15/88 (17%) had non ELVO ischaemic strokes or mimics (seizure, complex migraine, etc). 28/88 (32%) cases met indication for and were subsequently transferred to a CSC for consideration of ECR. The modelled median scene to groin time for the direct bypass strategy is 94 min whereas the median scene to groin time for the secondary transfer strategy is 109 min, giving a dif... Continued on ES/IODE ➡️ https://etcse.fr/0nC1 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.